Early vaccine trial aims to stop Cancer's return
NCT ID NCT03821272
Summary
This early-stage study tested whether a new vaccine called PepCan could safely prevent head and neck cancer from returning in patients who had recently finished treatment and were in remission. Seventeen participants received either the vaccine or a placebo injection over two years to see if it reduced cancer recurrence. Researchers also checked for immune system responses and changes in gut bacteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Conditions
Explore the condition pages connected to this study.